JP2011140516A - Composition having function of treating, preventing or ameliorating diabetes or diabetic complication, and drink containing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide safe, economical and convenient drinks having a function of treating, preventing or ameliorating diabetes or diabetic complication without greatly changing usual dietary habit. <P>SOLUTION: Drinks for treating, preventing or ameliorating diabetes or diabetic complication, include oligosaccharide to which mannose having 2-10 molecules is combined, at drinking concentration of 0.15-10 wt.%. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a composition having an action of treating, preventing or improving diabetes or diabetic complications comprising an oligosaccharide having mannose as a constituent sugar, and a beverage using the composition. The present invention also relates to effective use of unused resources.

  Conventionally, most coffee extraction residues have been treated as incineration or industrial waste. In recent years, coffee extraction residues have come to be used as raw materials for compost or activated carbon, but these are not sufficient from the viewpoint of advanced utilization of unused resources. Establishing this method is an important issue.

In recent years, lifestyle-related diseases such as diabetes, hypertension, and hyperlipidemia, which are rapidly increasing, are considered to be closely related to eating habits, and prevention by improving eating habits is regarded as important. In particular, the onset of diabetes is serious, and it is estimated that one out of every six adults and their reserves fall within this category. Type 2 diabetes, which accounts for 90% or more of diabetes, is caused by a combination of a decrease in insulin secretion from pancreatic β cells and a decrease in insulin sensitivity in the target organ, resulting in a decrease in insulin action and hyperglycemia. Further, once hyperglycemia occurs, insulin resistance due to glycotoxicity further occurs, resulting in a vicious circle. Diabetes has almost no subjective symptoms at an early stage, and its progression often leads to serious complications such as retinopathy, nephropathy, and neuropathy. Insulin resistance-improving drugs such as thiazolidine derivatives are used as therapeutic agents, but side effects due to long-term use have been reported. Therefore, it is considered important not only to prevent the onset of daily diet, but also to suppress and improve the progression of the disease even after the onset, that is, preventive medicine. This indicates that it is very important to suppress and prevent insulin resistance that causes diabetes and onset of hyperglycemia that is observed in the early stage of onset. Therefore, research has been conducted on the search for substances having a therapeutic / preventive effect on diabetes and the mechanism of its action, and as a food-derived component, the therapeutic / preventive effects on diabetes caused by soy isoflavone have been reported. However, its medicinal properties are low, and there is concern about the effect of excessive intake on hormone balance. The present applicant has so far obtained a food material containing a large amount of mannan, mainly a coffee-extracted koji hydrolyzate, wherein the sugar chain has a low content of sugar residues other than mannose residues and has a degree of polymerization of 1-10. We have found that manno-oligosaccharides have an excellent intestinal function with bifidobacteria growth action, serum lipid improvement function, etc., but whether manno-oligosaccharides have a treatment, prevention or improvement action for diabetes or diabetic complications It was completely unknown.
JP 2003-211 A JP 2003-196 JP 2003-286166 A

  It is an object of the present invention to provide a safe, economical and simple beverage that has no significant change in normal eating habits and has an effect of treating, preventing, or improving diabetes or diabetic complications. It is said.

As a result of diligent studies to solve these problems, the present inventors have found that sugar residues other than mannose residues are present in sugar chains from food materials containing a large amount of mannan, mainly coffee extract koji hydrolysates. A mannooligosaccharide having a low group content and a degree of polymerization of 2 or more and 10 or less, that is, a mannooligosaccharide bound to 2 or more and 10 molecules or less of mannose has been found to have a therapeutic, preventive or ameliorating action for diabetes or diabetic complications. The invention has been completed. Further, by obtaining a mannooligosaccharide having a degree of polymerization of 2 or more and 10 or less and having no sugar residue other than mannose residues in a non-colored and acid-free sugar chain, the scope of application to food is dramatically expanded. I found out that I can do it.

Accordingly, aspects of the present invention are as follows.
A beverage for treating, preventing, or ameliorating diabetes or diabetic complications, comprising a drinking concentration of 0.15 to 10% by weight of an oligosaccharide bound with 1.2 to 10 molecules of mannose.
The drink which suppresses the blood glucose level rise at the time of a sugar load which contains the oligosaccharide which the mannose of 2.2 or more and 10 molecules or less couple | bonded with the drinking concentration 0.15-10 weight%.
3. A beverage that lowers blood glucose level, comprising a drinking concentration of 0.15 to 10% by weight of an oligosaccharide to which mannose of 2 to 10 molecules is bound.
The drink which improves insulin resistance formed by containing the oligosaccharide which the 4.2 to 10 molecule mannose couple | bonded with the drink concentration 0.15-10 weight%.
5. The beverage according to any one of claims 1 to 4, wherein the oligosaccharide is an oligosaccharide having 2 to 6 mannose units in the molecule.
6). The beverage according to any one of claims 1 to 5, wherein the oligosaccharide is obtained by hydrolyzing mannan.
7). The beverage according to claim 6, wherein the mannan of the preceding item is obtained from coffee beans and / or a coffee extraction residue.
8). The beverage according to any one of claims 1 to 7, wherein the oligosaccharide is β-1,4-mannooligosaccharide.
9. The beverage according to any one of claims 1 to 8, wherein the beverage is a liquid coffee beverage, a liquid tea beverage, a liquid fruit beverage, an instant coffee, a powdered coffee mix beverage, a powdered tea beverage, or a powdered fruit juice beverage.

  By adding manno-oligosaccharides that have the effect of treating, preventing or ameliorating diabetes or diabetic complications to food and drink, it can be easily and economically consumed in daily eating habits. Can be expected to have a therapeutic, preventive, or ameliorating effect. Manno-oligosaccharides having an effect of treating, preventing, or ameliorating diabetes or diabetic complications can be obtained from wastes such as coffee extraction residues, and therefore, resources that have not been conventionally used can be effectively utilized.

Next, the contents of the present invention will be described in detail.
In the present invention, “mannooligosaccharide” means an oligosaccharide having mannose which is a monosaccharide as a constituent element. Here, the term “oligosaccharide” generally refers to a substance that is located between a monosaccharide and a polysaccharide and consists of a glycosyl bond of a certain small number of monosaccharide molecules. That is, it is a polymer with a relatively small number of monosaccharides bound thereto. The term “oligosaccharide” refers to a composition containing a plurality of oligosaccharides having various constituent monosaccharides. And, the term “manno-oligosaccharide” refers to a composition containing a plurality of oligosaccharides having various constituent monosaccharides.

In this specification, “DP” may be used to indicate the degree of polymerization of the oligosaccharide. DP means the number of monosaccharides constituting the oligosaccharide. That is, mannose which is a monosaccharide is expressed as “DP1”, and a mannooligosaccharide composed of four mannoses has a polymerization degree of 4,
That is, it is expressed as “DP4”. That is, when it is referred to as “manno-oligosaccharide having 2 to 10 molecules of mannose bonded”, it should be understood that the composition is an oligosaccharide having a polymerization degree of 2 to 10.

  The manno-oligosaccharide used in the present invention is preferably a composition of a plurality of types of oligosaccharides having 2 to 10 molecules and mannose bound thereto. A particularly preferable oligosaccharide is a composition of oligosaccharide in which 2 to 6 molecules of mannose are bound.

  One aspect of the present invention is a beverage comprising a drinking concentration of 0.15 to 10% by weight of a composition containing the above-described manno-oligosaccharide and having an effect of treating, preventing, or improving diabetes or diabetic complications. . Here, the term “composition having the effect of treating, preventing or ameliorating diabetes or diabetic complications” generally means a composition having an effect of treating, preventing or ameliorating diabetes or diabetic complications. Therefore, a composition having an effect of treating, preventing or ameliorating diabetes or diabetic complications can be produced using such oligosaccharide.

  Another aspect of the present invention includes a composition having an effect of treating, preventing, or improving diabetes or diabetic complications, and having an effect of treating, preventing, or improving diabetes or diabetic complications of a person. It is a beverage characterized by being. Manno-oligosaccharide "contains a drinking concentration of 0.15 to 10% by weight" means that if the beverage is a beverage that can be drunk immediately, such as a liquid coffee beverage, a liquid tea beverage or a liquid fruit juice beverage, It means that the concentration of manno-oligosaccharides in the beverage is 0.15 to 10% by weight. In addition, when the beverage is a beverage such as instant coffee, powdered coffee mix beverage, powdered tea beverage or powdered fruit juice beverage that is dissolved in water or hot water during drinking, the concentration of manno-oligosaccharides in the beverage obtained by dissolution is 0.15 to It means 10% by weight.

  Now, the manno-oligosaccharide used for this invention can be manufactured by hydrolyzing mannan and extracting soluble raw solid content. Here, the raw material mannan can be obtained, for example, by extracting from copra meal, flakes obtained from coconut palm, South African coconut plants Huacal Palm, tsukunei mannan, yam mannan. Mannan thus obtained is treated by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation, preferably activated carbon treatment, adsorption resin treatment, ion A sugar mixture can be obtained by purification by a method such as an exchange resin treatment or an ion exchange membrane treatment. Such a mixture contains a manno-oligosaccharide having an effect of treating, preventing or ameliorating the above-mentioned diabetes or diabetic complications. Therefore, the composition thus obtained is a composition having an effect of treating, preventing, or improving diabetes or diabetic complications of the present invention. Furthermore, the composition having an effect of treating, preventing, or improving diabetes or diabetic complications of the present invention is a galacto contained in glucomannan, locust bean gum, guar gum and the like contained in konjac potato, lily, daffodil, laver and the like. Mannan is treated by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment It may be produced by separating and purifying by the above method and increasing the ratio of mannose as a constituent sugar.

  Therefore, in the present specification, the term “mannan” is not limited to mannan which is a polysaccharide having only D-mannose as a structural unit, but also galactomannan and glucomannan which are polysaccharides having mannose and galactose or glucose as structural units. To be included. In addition, D-mannose is an aldohexose, and the configuration of the hydroxyl group bonded to the carbon adjacent to the carboxyl group in D-glucose is reversed.

  Further, the composition having an effect of treating, preventing or improving diabetes or diabetic complications of the present invention is a method for acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, microbial fermentation of green coffee beans or roasted coffee beans. It can be obtained by treating with one or more methods selected from among them, and purifying with a method such as activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, ion exchange membrane treatment or the like.

  Alternatively, the used coffee residue is treated by one or more methods selected from acid hydrolysis, high-temperature heat hydrolysis, enzyme hydrolysis, and microbial fermentation, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment. It can also be obtained by purification by a method such as ion exchange membrane treatment. In general, when roasted and ground coffee is extracted with a commercial extractor, galactose, which is a side chain of galactomannan contained in roasted coffee, is solubilized or arabinogalactan is solubilized by hydrolysis. . Therefore, it is presumed that the coffee residue is rich in mannan and has a linear structure. On the other hand, although cellulose is hardly decomposed and remains as a residue, manno-oligosaccharide can be obtained by appropriately selecting and extracting conditions for specifically hydrolyzing mannan without decomposing cellulose.

  Examples of the method for decomposing the coffee extraction residue include, but are not limited to, a method of hydrolyzing with an acid and / or high temperature, a method of decomposing with an enzyme, and a method of decomposing by microbial fermentation. Methods for hydrolyzing with an acid and / or high temperature are disclosed in JP-A Nos. 61-96947 and 2-200147. It is possible to hydrolyze spent coffee residue that comes out in a commercial coffee multistage extraction system by adding an acid catalyst in a reaction vessel or by treating it at a high temperature for a short time without adding an acid catalyst. It can also be obtained by decomposing. Although it is convenient to use a tubular plug flow reactor, good results can be obtained with any reactor that is suitable for carrying out a reaction at a relatively high temperature for a short time. By adjusting the reaction time and reaction temperature, solubilizing and hydrolyzing, mannan of DP10-40 can be decomposed into DP2-10 mannooligosaccharide, and then separated from coffee residue to extract mannooligosaccharide. Here, the coffee extraction residue means a so-called coffee extraction cake after the roasted and ground coffee is extracted with a solvent such as water in the air or under pressure.

  The composition having the effect of treating, preventing, or ameliorating diabetes or diabetic complications of the present invention is a hydrolysis treatment of coffee beans (including roasted coffee beans and roasted and ground coffee beans) and / or coffee extraction residues. If you want to obtain it, there are no particular restrictions on the type of coffee beans used or the production area, and any coffee beans such as Arabica, Robusta, and Riberica can be used, and coffee beans from any production area such as Brazil and Colombia should be used. And only one kind of beans may be used alone or two or more kinds of blended beans may be used. Usually, even poor quality coffee beans or small coffee beans that are discarded as having no commercial value can be used. Coffee beans roasted in a shallow roast, shallow roast, medium roast, deep roast by a roasting machine (direct fire, hot air, far red, charcoal fire type, etc.) generally used for the above coffee beans, and this roast Roasted and ground coffee (coarse ground, medium ground, medium ground, medium ground, fine ground, etc.) Can be used).

  In addition, the coffee extraction residue may be extracted under normal pressure or under pressure as long as it is extracted after roasted and ground coffee in a normal liquid coffee or instant coffee manufacturing process, and coffee of any origin and process. Even extraction residues can be used.

Here, some of the hydrolysis treatments will be described in detail. As a method of decomposing with an enzyme, for example, a coffee extraction residue may be suspended in an aqueous medium, and then commercially available cellulase, hemicellulase, etc. may be added thereto and suspended with stirring. There are no particular problems with the amount of enzyme, the temperature at which it acts, and other conditions as long as it is the amount, temperature, and conditions used in normal enzyme reactions, depending on the optimum amount of enzyme used, temperature, conditions, and other factors. What is necessary is just to select suitably.

  As a method of decomposing by microbial fermentation, for example, a microorganism that produces cellulase, hemicellulase, etc. may be inoculated and cultured in a coffee extraction residue suspended in an aqueous medium. The microorganism to be used may be any microorganism that produces an enzyme that decomposes mannan in the coffee extraction residue such as bacteria and basidiomycetes, and the culture conditions and the like may be appropriately selected depending on the microorganism to be used.

  The reaction solution containing a composition having an action of treating, preventing or ameliorating diabetes or diabetic complications containing the manno-oligosaccharide obtained by the above method can be purified as necessary. As purification methods, bone charcoal, activated carbon, carbonic acid saturation method, adsorption resin, magnesia method, solvent extraction method, etc. are used for decolorization and deodorization, and ion exchange resin, ion exchange membrane, electrodialysis, etc. are used for desalting and deoxidation Can be mentioned. The combination of the purification methods and the purification conditions may be appropriately selected according to the amount of pigment, salt, acid, etc. in the reaction solution containing the manno-oligosaccharide and other factors.

  The present invention also relates to an orally ingestible composition, particularly a beverage, containing a composition having an action of treating, preventing, or improving diabetes or diabetic complications according to the present invention described above. Furthermore, the composition having the effect of treating, preventing, or improving diabetes or diabetic complications of the present invention can be used not only in the above beverages but also in a wide range of fields such as foods, cosmetics, pharmaceuticals, and feeds. The composition having the effect of treating, preventing or ameliorating diabetes or diabetic complications employed in the present invention may be administered as a pharmaceutical or quasi-drug as a therapeutic or preventive preparation for diabetes or diabetic complications. . Preferably, it can also be administered as a pharmaceutical composition that can be produced by known methods. Examples of the pharmaceutical composition include tablets, capsules, powders, granules, solutions and syrups. The composition having an effect of treating, preventing, or improving diabetes or diabetic complications of the present invention has the effect of treating, preventing, or improving diabetes or diabetic complications, particularly when taken by the human mouth as a food or drink. Demonstrate. The amount of intake or dose for exerting the effectiveness of the present invention is not particularly limited, and can be appropriately increased or decreased depending on the weight or age of the intaker or patient, the type of disease, and symptoms. Generally, it can be used in the range of 0.1 g to 40 g, preferably 0.5 g to 20 g per day for an adult.

Thus, when ingesting manno-oligosaccharides from beverages, for example, assuming that 300 milliliters of beverage is ingested per day, the beverage of the present invention has a manno-oligosaccharide composition at a drinking concentration of about 0.03 to 13% by weight, preferably The content should be 0.15 to 10% by weight. In order to exhibit treatment, prevention, or amelioration of diabetes or diabetic complications, it is necessary to ingest about 0.5 to 20 g of manno-oligosaccharide per person per day. Assuming that the beverage of the present invention is ingested by 100 g three times a day, it is preferable to contain about 0.17 to 6.67 g of manno-oligosaccharide per cup of beverage. For example, the amount of conventional manno-oligosaccharide contained in a single instant coffee is about 0.02 to 0.1 g, which is much less than the beverage according to the present invention, and has the effect of treating, preventing, or improving diabetes or diabetic complications. Will not bring. Therefore, the manno-oligosaccharide obtained by the method mentioned above can be added to a drink, and the drink which strengthened the manno-oligosaccharide can be manufactured.

When ingesting such a beverage, it is highly preferable if it can be dissolved in water or the like and immediately made on the spot. Therefore, the present invention is a beverage raw material selected from the group consisting of 0.15 to 20 g of an oligosaccharide to which 2 to 10 molecules of mannose are bound and powdered coffee, tea leaves, powdered tea, and powdered fruit juice. It also relates to a powdered beverage mix containing 1-10 g. A powdered beverage mix containing manno-oligosaccharides that provides a treatment, prevention or amelioration effect for diabetes or diabetic complications is also preferred from the standpoint of product storage. Examples of such powdered beverage mixes include instant coffee typified by instant coffee, tea leaves, green tea leaves, tea leaves typified by oolong tea leaves, powdered tea obtained by drying tea beverages, and powdered fruit juice. Can be mentioned. When mixing manno-oligosaccharide and instant coffee, it is preferable to mix manno-oligosaccharide 0.15-20g with respect to instant coffee 1.5g-2.0g, for example. Similarly, it is preferable to mix 0.15 to 20 g of manno-oligosaccharides with respect to 0.1 g to 1.0 g of powdered tea and 0.15 g to 20 g of manno-oligosaccharides with respect to 4.0 to 10 g of powdered fruit juice. Instant coffee, powdered tea and powdered fruit juice can be appropriately produced by conventional techniques. In addition, the powdered beverage mix of the present invention is appropriately added with additives such as sweeteners, fragrances, colorants, thickeners, foaming agents, emulsifiers, pH adjusters, vegetable oils and fats or milk ingredients such as milk components. Can be included.

  In the present invention, liquid coffee is a composition having a therapeutic, preventive, or ameliorating action for diabetes or diabetic complications prepared by hydrolyzing a coffee extraction residue with acid and / or heat and containing oligosaccharides in high purity. It can also be used as it is added to instant coffee, etc., but it is better to add a composition that has been purified by decolorization, deodorization, deoxidation, etc. with activated carbon, ion exchange resin, solvent, etc. Can provide a richer flavor and aroma of coffee.

  Here, as a drink, what is called a liquid drink marketed in a can or what is called a PET bottle container is mentioned. Examples of the powdered beverage mix include instant coffee mix, instant tea mix, and instant fruit juice beverage mix. Examples of instant coffee include what is called soluble powdered coffee obtained by removing moisture by spraying or freeze-drying an extract obtained by extracting roast and ground coffee with hot water, and coffee mix beverages include soluble powdered coffee with sugar and creaming. The drink etc. which added and mixed powder etc. are mentioned.

  In order to solve the above-mentioned problems, the present inventors include an oligosaccharide to which 2 to 10 molecules of mannose obtained by the above-described method are bound, to treat diabetes or diabetic complications Using a beverage having a preventive or ameliorating action, the glucose tolerance and the effect of improving hyperglycemia were studied. In addition, the effect on blood glucose levels in humans was also investigated. As a result, it was found that glucose tolerance and hyperglycemia improving effects in animals and human blood glucose level lowering effects were expressed, and the present invention was completed.

Using the composition having the effect of treating, preventing, or improving diabetes or diabetic complications of the present invention, the glucose tolerance and hyperglycemia improving effects in animals and the influence on human blood glucose levels were examined. This example specifically describes the embodiment of the present invention, and is not intended to limit the scope of the present invention.
Example 1
Preparation of Manno-oligosaccharide Roasted and ground coffee obtained by a conventional method was extracted with a commercially used percolation system, and the remaining coffee extraction residue was used.

The coffee extraction residue was first pulverized to a particle size of about 1 mm in order to facilitate sending to the reactor. Next, a slurry composed of water and the pulverized product and having a total solid concentration of about 14% by weight was prepared and heat-treated in a 4 m hot plug flow reactor. Pumped to the plug reactor with high pressure steam at a rate corresponding to a residence time of 8 minutes and maintained at about 210 ° C. using a 6.35 mmφ orifice. Thereafter, the reaction was stopped by spraying under atmospheric pressure. The resulting slurry was filtered to separate a liquid containing soluble solids from insoluble solids. This soluble solid-containing liquid is decolorized with activated carbon and an adsorption resin, further desalted with an ion exchange resin, concentrated and dried to contain an oligosaccharide in which 1 to 10 molecules of monosaccharides mainly composed of mannose are bonded. The product was obtained in 14% yield.

  The DP distribution of the oligosaccharide contained in the composition having an effect of treating, preventing or ameliorating diabetes or diabetic complications thus obtained is DP1; 2.4%, DP2; 26.6%, DP3; 20.2%, DP4; 17.8%, DP5; 10.9%, DP6; 8.9%, DP7; 6.0%, DP8; 3.6%, DP9; 1.9%, DP10 At 1.7%, the mannose residue content in the sugar chain is 90%, but the DP distribution and the mannose residue content in the sugar chain can take various values depending on the hydrolysis conditions. Oligosaccharide DP1 as mannose, DP2 as mannobiose, DP3 as mannotriose, DP4 as mannotetraose, DP5 as mannopentaose, DP6 as mannohexaose, etc. DP7 was mannoheptaose, DP8 was mannooctaose, DP9 was mannononaose, DP10 was mannodekaose, and the binding mode was β-1,4 bond. The following experiment was conducted using the manno-oligosaccharide thus obtained.

<Example 1>
Experiments on the effect of manno-oligosaccharide administration on glucose tolerance
ICR female mice were used in the experiment. Pre-breeding for a week for quarantine and acclimatization period,
Individuals with no abnormalities in weight transition and general condition were donated to the experiment. The breeding was carried out in a cycle of 12 hours for light and dark, with temperature and humidity controlled. During the quarantine / acclimation period, the feed was freely ingested with the powdered feed CE-2 (Japan Claire Co., Ltd.), and the drinking water was freely infused with tap water. After the preliminary breeding, one group was divided into 6 groups so that the average body weights were almost equal. The group composition was 4 groups: a normal group, a high fat diet group, a high fat diet group containing 3% mannooligosaccharides, and a high fat diet group containing 9% mannooligosaccharides. As for the feed, the normal group was fed the same as in the preliminary breeding, and the high fat diet group was fed a high fat diet having the following composition. (High fat diet composition; beef tallow 40% by weight, corn starch 10% by weight, sugar 9% by weight, AIN76TM mixed vitamin 1% by weight, AIN76TM mixed mineral 4
(Weight%, casein 36 weight%) Manno-oligosaccharide-containing high-fat diet group added 3% by weight or 9% by weight of manno-oligosaccharide to the feed. The increase was adjusted with casein. A glucose tolerance test by glucose administration was performed at 12 weeks of breeding. That is, after fasting the mice for 16 hours, glucose (0.8 g / individual) was orally administered. Blood was collected from the tail at 60 minutes, 120 minutes, and 180 minutes after administration, and the blood glucose concentration was measured.

The results of the glucose tolerance test are shown in FIG. Compared with the normal group, the high fat diet group showed a significantly high value at 60 minutes, and maintained a high value throughout. Since this experiment was administered after fasting for 16 hours, it was considered that there was no effect of sugar in the diet, and thus it was suggested that impaired glucose metabolism occurred in the high fat diet group. Obesity has been shown to induce a decline in insulin function (insulin resistance), a hormone involved in glucose metabolism. Therefore, it was considered that the high-fat diet group showed a high blood glucose concentration due to a decrease in insulin action due to obesity.
On the other hand, the blood glucose levels of the high fat diet group containing 3% mannooligosaccharide and the high fat diet group containing 9% mannooligosaccharide remained at the same level as the normal group. Moreover, it was a significantly low value compared with the high fat diet group (p <0.05 or p <0.01). These showed normal sugar metabolism despite having ingested a high fat diet, and it was revealed that glucose tolerance was improved by administration of manno-oligosaccharide (FIG. 1).
<Example 2>
Experiment on the effect of manno-oligosaccharide administration on the blood glucose level of diabetic rats We purchased Wistar male rats (Nippon Charles River Co., Ltd.)
After pre-breeding in a breeding room controlled at 60% humidity for one week, healthy rats were used for the experiment. Streptozotocin (65 mg / kg) was administered into the rat abdomen to prepare diabetes model rats. Individuals with a blood glucose level of 300 mg / dl or more were classified as diabetic rats, and the blood glucose level was used as an index for grouping as 5 animals per group. The group composition was three groups: a control group, a 3% mannooligosaccharide administration group, and a 15% mannooligosaccharide administration group. During the breeding period, feed CE-2 (Nippon Claire Co., Ltd.) and tap water were freely ingested. Samples were administered by gavage and the test group was administered 3% or 15% mannooligosaccharide solution three times a day (6 ml / day). An equal amount of distilled water was orally administered to the control group. The breeding period was 28 days, blood was collected under non-fasting conditions on the 14th day of breeding, and fasted on the 28th day of breeding, and the blood glucose level was measured. Furthermore, the glucose tolerance test was conducted as described in Example 1 during the breeding period.

The blood glucose level results are shown in Table 1, and the glucose tolerance test results are shown in FIG. On the 14th day after administration, the blood sugar level at non-fasting was significantly lower in the 15% manno-oligosaccharide administration group than in the control group (p <0.01). Furthermore, in the fasting blood glucose level on the 28th day after administration, the 3% and 15% mannooligosaccharide administered groups showed significantly lower blood glucose levels than the control group (p <0.001). In the glucose tolerance test, the blood glucose level tended to be lower in the 15% mannooligosaccharide administration group than in the control group. These results suggest that administration of manno-oligosaccharide can be expected to improve hyperglycemia and glucose tolerance due to diabetes.

<Example 3>
Experiment on the effect of manno-oligosaccharide administration on human blood glucose level The effect of drinking manno-oligosaccharide-containing beverages on human blood glucose level was investigated.

The subjects were those who had a high blood glucose level within the normal range (n = 5). The test beverage was liquid coffee, and was prepared by filling a concentrated coffee extract, mannooligosaccharide (3 g / 300 ml), artificial sweetener with water and diluting, and UHT sterilized filling into a 900 ml PET bottle. The ingestion amount and period were 900 ml per day for 4 weeks, and blood was collected before ingestion (day 0) and at 4 weeks to measure blood glucose levels.

The results are shown in Table 2. The fasting blood glucose level (90.0 ± 3.0 mg / dL) at 4 weeks was significantly lower than the fasting blood glucose level (96.0 ± 3.6 mg / dL) before ingestion (p). <0.05)
.

  These results suggest that the administration of mannooligosaccharide can be expected to lower the blood glucose level.

  In addition, when the liquid coffee (brand name: blendy bottle coffee, Ajinomoto General Foods) which is a conventional product was drunk for 12 weeks as a control, such a decrease in blood glucose level was not confirmed.

  The beverage used for the treatment, prevention or amelioration of diabetes or diabetic complications of the present invention contains a manno-oligosaccharide having these actions, and can be specifically produced by hydrolyzing mannan. The effect of treating, preventing, or ameliorating diabetes or diabetic complications can be expected by daily intake of the beverage used for the treatment, prevention, or amelioration of diabetes or diabetic complications of the present invention. As a raw material of the composition used for the treatment, prevention, or improvement of diabetes or diabetic complications of the present invention, for example, coffee beans or coffee extract residues can be used. That is, it becomes possible to prepare a composition having an effect of treating, preventing, or improving diabetes or diabetic complications from a coffee extraction residue that has been treated as waste, and to take it together with food and drink. Therefore, it is a very useful invention from the viewpoint of reuse of waste resources in addition to the health improvement effect.

FIG. 3 is a diagram showing the results of a glucose tolerance test in Example 1. FIG. 4 is a diagram showing the results of a glucose tolerance test in Example 2.

Claims (1)

  A pharmaceutical product for treating or ameliorating diabetes or diabetic complications, comprising an oligosaccharide to which 2 to 10 molecules of mannose are bound, obtained by high-temperature heat hydrolysis of coffee beans and / or coffee extraction residue.

Images